Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00123)
Name |
Sarcopenia
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: FB32
|
Full List of Target(s) of This Ferroptosis-centered Disease
Cystine/glutamate transporter (SLC7A11)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Sarcopenia [ICD-11: FB32] | ||||
Responsed Drug | Ferric citrate | Investigative | |||
Responsed Regulator | Cellular tumor antigen p53 (TP53) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Glutathione metabolism | hsa00480 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | C2C12 cells | Normal | Mus musculus | CVCL_0188 | |
In Vivo Model |
The 8-week- and 40-week-old male SAMP8 mice were purchased from the model animal research center of Zhishan Institute of Healthcare Research Co., Ltd. (Beijing, China). All the mice were kept in an SPF grade animal facility at 24 with a relative humidity of 50%-60%, and in a light/dark cycle of 12 h/12 h.
Click to Show/Hide
|
||||
Response regulation | Ferric citrate induced ferroptosis in C2C12 cells, as well as impaired their differentiation from myoblasts to myotubes. Iron overload upregulated the expression of P53, which subsequently repressed the protein level of Slc7a11 (solute carrier family 7, member 11), a known ferroptosis-related gene. Targeting iron accumulation and ferroptosis might be a therapeutic strategy for treating sarcopenia. | ||||